Literature DB >> 12643750

Controlled release of proteins from their poly(ethylene glycol) conjugates: drug delivery systems employing 1,6-elimination.

Richard B Greenwald1, Karen Yang, Hong Zhao, Charles D Conover, Stanford Lee, David Filpula.   

Abstract

Several tripartate releasable PEG linkers (rPEG) that can provide anchimeric assistance to hydrolysis (cyclization prodrugs) were prepared and, after conjugation to lysozyme demonstrated rapid cleavage in rat plasma compared to nonassisted, permanently bound PEG. By varying the chemical structure and adding steric hindrance, the half-life of the protein conjugates can be adjusted from slow to very fast. The pharmacokinetics (PK) of regeneration of native protein, from various rPEG conjugates can, for the first time, be easily followed in the rat using green fluorescent protein. The PK in mice was also determined for rPEG-Interleukin 2 (rPEG-IL-2) conjugates in vivo using an ELISA assay. Thus, a systematic study of rPEGylated proteins, either in vivo or in vitro during processing, has been investigated based on regeneration of native protein. The employment of releasable PEG polymers substantially broadens the applications of PEGylation drug delivery technology by introducing the benefits of controlled release of native protein therapeutics.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12643750     DOI: 10.1021/bc025652m

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   4.774


  9 in total

1.  Alkyne- and 1,6-elimination- succinimidyl carbonate - terminated heterobifunctional poly(ethylene glycol) for reversible "Click" PEGylation.

Authors:  Yumei Xie; Shaofeng Duan; M Laird Forrest
Journal:  Drug Discov Ther       Date:  2010

2.  Designing hydrogels for controlled drug delivery.

Authors:  Jianyu Li; David J Mooney
Journal:  Nat Rev Mater       Date:  2016-10-18       Impact factor: 66.308

Review 3.  Central nervous system delivery of large molecules: challenges and new frontiers for intrathecally administered therapeutics.

Authors:  Ryan G Soderquist; Melissa J Mahoney
Journal:  Expert Opin Drug Deliv       Date:  2010-03       Impact factor: 6.648

4.  Hydrogel drug delivery system with predictable and tunable drug release and degradation rates.

Authors:  Gary W Ashley; Jeff Henise; Ralph Reid; Daniel V Santi
Journal:  Proc Natl Acad Sci U S A       Date:  2013-01-23       Impact factor: 11.205

5.  Multivalent and flexible PEG-nitrilotriacetic acid derivatives for non-covalent protein pegylation.

Authors:  Anna Mero; Tetsuya Ishino; Irwin Chaiken; Francesco M Veronese; Gianfranco Pasut
Journal:  Pharm Res       Date:  2011-05-25       Impact factor: 4.200

6.  Unique uptake of acid-prepared mesoporous spheres by lung epithelial and mesothelioma cells.

Authors:  Steven R Blumen; Kai Cheng; Maria E Ramos-Nino; Douglas J Taatjes; Daniel J Weiss; Christopher C Landry; Brooke T Mossman
Journal:  Am J Respir Cell Mol Biol       Date:  2006-10-12       Impact factor: 6.914

7.  PEGylation of brain-derived neurotrophic factor for preserved biological activity and enhanced spinal cord distribution.

Authors:  Ryan G Soderquist; Erin D Milligan; Evan M Sloane; Jacqueline A Harrison; Klarika K Douvas; Joseph M Potter; Travis S Hughes; Raymond A Chavez; Kirk Johnson; Linda R Watkins; Melissa J Mahoney
Journal:  J Biomed Mater Res A       Date:  2009-12       Impact factor: 4.396

8.  PEGylation of interleukin-10 for the mitigation of enhanced pain states.

Authors:  Ryan G Soderquist; Erin D Milligan; Jacqueline A Harrison; Raymond A Chavez; Kirk W Johnson; Linda R Watkins; Melissa J Mahoney
Journal:  J Biomed Mater Res A       Date:  2010-06-01       Impact factor: 4.396

9.  Impact of Linker Modification and PEGylation of Vancomycin Conjugates on Structure-Activity Relationships and Pharmacokinetics.

Authors:  Florian Umstätter; Julia Werner; Leah Zerlin; Eric Mühlberg; Christian Kleist; Karel D Klika; Tobias Hertlein; Barbro Beijer; Cornelius Domhan; Stefan Zimmermann; Knut Ohlsen; Uwe Haberkorn; Walter Mier; Philipp Uhl
Journal:  Pharmaceuticals (Basel)       Date:  2022-01-28
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.